Jim Banting
Chief Executive Officer at PARTEQ Innovations
Profile
Dr. Jim Banting is President & Chief Executive Officer at PARTEQ Innovations.
Prior to joining PARTEQ Innovations, Dr. Banting was employed as Head of Business Development by Sigma-Tau Pharmaceuticals, Inc., a U.S.
company focused on rare diseases.
Previously, he spent six years in the business development group of the U.S.
biotechnology company Human Genome Sciences.
In that role, he led the due diligence and negotiation of a number of in- and out-licensing, manufacturing, platform, and co-development related collaborations.
He has also worked at the proteomics company Caprion, securing numerous biomarker discovery collaborations with industry partners.
His career began as a co-founder of the Queen's spin-off company Vaxis Therapeutics that was funded by venture capitalists.
After growing the company, Dr. Banting served as the business development lead on the sale of Vaxis to a U.S.
specialty pharmaceutical company.
Dr. Banting graduated from Queen's in 1993 with an honours degree in Life Sciences.
He earned his doctorate in pharmacology at Queen's.
Jim Banting active positions
| Companies | Position | Start |
|---|---|---|
PARTEQ Innovations
 PARTEQ Innovations Investment ManagersFinance Founded in 1987 by Queen's University at Kingston, Ontario, PARTEQ Innovations is a venture capital firm. | Chief Executive Officer | - |
Former positions of Jim Banting
| Companies | Position | End |
|---|---|---|
Vaxis Therapeutics Corp
 Vaxis Therapeutics Corp Pharmaceuticals: MajorHealth Technology Part of DMK Pharmaceuticals Corp., Vaxis Therapeutics Corp manufactures and researches pharmaceutical products. The company is based in Kingston, Canada. Vaxis Therapeutics was acquired by Cellegy Pharmaceuticals, Inc. on November 29, 2001 for $4 million. | Corporate Officer/Principal | - |
Leadiant Biosciences, Inc.
 Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Training of Jim Banting
| Queen's University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
PARTEQ Innovations
PARTEQ Innovations Investment ManagersFinance Founded in 1987 by Queen's University at Kingston, Ontario, PARTEQ Innovations is a venture capital firm. | Finance |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Vaxis Therapeutics Corp
Vaxis Therapeutics Corp Pharmaceuticals: MajorHealth Technology Part of DMK Pharmaceuticals Corp., Vaxis Therapeutics Corp manufactures and researches pharmaceutical products. The company is based in Kingston, Canada. Vaxis Therapeutics was acquired by Cellegy Pharmaceuticals, Inc. on November 29, 2001 for $4 million. | Health Technology |
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Health Technology |
- Stock Market
- Insiders
- Jim Banting
